## Nadia Howlader

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11243181/publications.pdf

Version: 2024-02-01

22 papers 6,866 citations

430442 18 h-index 713013 21 g-index

22 all docs 22 docs citations

times ranked

22

10815 citing authors

#	Article	IF	CITATIONS
1	Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer, 2018, 124, 2785-2800.	2.0	1,066
2	US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. Journal of the National Cancer Institute, 2014, 106, .	3.0	969
3	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine, 2020, 383, 640-649.	13.9	893
4	Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist, 2007, 12, 20-37.	1.9	889
5	The Decrease in Breast-Cancer Incidence in 2003 in the United States. New England Journal of Medicine, 2007, 356, 1670-1674.	13.9	879
6	Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. Journal of the National Cancer Institute, 2015, 107, djv048.	3.0	710
7	Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data. Journal of the National Cancer Institute, 2010, 102, 1584-1598.	3.0	376
8	Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 632-641.	1.1	310
9	Cancer Survival: An Overview of Measures, Uses, and Interpretation. Journal of the National Cancer Institute Monographs, 2014, 2014, 145-186.	0.9	197
10	Breast Cancer Incidence Rates in U.S. Women Are No Longer Declining. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 733-739.	1.1	111
11	Use of Imputed Population-based Cancer Registry Data as a Method of Accounting for Missing Information: Application to Estrogen Receptor Status for Breast Cancer. American Journal of Epidemiology, 2012, 176, 347-356.	1.6	75
12	Providing Clinicians and Patients With Actual Prognosis: Cancer in the Context of Competing Causes of Death. Journal of the National Cancer Institute Monographs, 2014, 2014, 255-264.	0.9	72
13	The Impact of Underreported Veterans Affairs Data on National Cancer Statistics: Analysis Using Population-Based SEER Registries. Journal of the National Cancer Institute, 2009, 101, 533-536.	3.0	60
14	Cancerâ€specific mortality, cure fraction, and noncancer causes of death among diffuse large Bâ€cell lymphoma patients in the immunochemotherapy era. Cancer, 2017, 123, 3326-3334.	2.0	60
15	Overview of breast cancer collaborative stage data items—their definitions, quality, usage, and clinical implications: A review of SEER data for 2004â€2010. Cancer, 2014, 120, 3771-3780.	2.0	58
16	Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 174-179.	1.1	52
17	Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1289-1296.	1.1	32
18	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1332-1341.	1.1	28

#	Article	IF	CITATIONS
19	Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1544-1551.	1.1	19
20	Imputing estrogen receptor (ER) status in a populationâ€based cancer registry: a sensitivity analysis. Statistics in Medicine, 2017, 36, 1014-1028.	0.8	5
21	Measuring progress against cancer in the Azores, Portugal: Incidence, survival, and mortality trends and projections to 2025. Cancer Epidemiology, 2020, 69, 101810.	0.8	3
22	Monitoring the Burden of Cancer in the United States. , 2010, , 3-23.		2